Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

INCORVAIA, Lorena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.822
EU - Europa 6.072
AS - Asia 5.365
Continente sconosciuto - Info sul continente non disponibili 920
SA - Sud America 890
AF - Africa 170
OC - Oceania 13
Totale 25.252
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.470
SG - Singapore 2.101
RU - Federazione Russa 1.813
IT - Italia 1.553
CN - Cina 1.164
BR - Brasile 709
DE - Germania 588
HK - Hong Kong 514
VN - Vietnam 489
FI - Finlandia 426
PL - Polonia 393
GB - Regno Unito 281
BD - Bangladesh 275
FR - Francia 269
JP - Giappone 200
CA - Canada 174
UA - Ucraina 155
IN - India 134
IE - Irlanda 132
NL - Olanda 102
KR - Corea 88
SE - Svezia 85
IQ - Iraq 73
MX - Messico 64
TR - Turchia 54
AR - Argentina 52
ES - Italia 47
RO - Romania 47
AT - Austria 46
ZA - Sudafrica 44
BE - Belgio 35
EC - Ecuador 35
MA - Marocco 28
JM - Giamaica 27
MY - Malesia 26
CO - Colombia 24
ID - Indonesia 24
IR - Iran 23
UZ - Uzbekistan 23
PK - Pakistan 22
VE - Venezuela 22
AE - Emirati Arabi Uniti 20
CI - Costa d'Avorio 19
NP - Nepal 19
EG - Egitto 17
SA - Arabia Saudita 16
CL - Cile 15
KE - Kenya 15
NI - Nicaragua 15
BG - Bulgaria 13
CR - Costa Rica 13
PH - Filippine 13
AU - Australia 12
CZ - Repubblica Ceca 12
HN - Honduras 11
LT - Lituania 11
PY - Paraguay 11
CH - Svizzera 10
TN - Tunisia 10
UY - Uruguay 10
PS - Palestinian Territory 9
TW - Taiwan 9
KZ - Kazakistan 8
PT - Portogallo 8
AZ - Azerbaigian 7
DZ - Algeria 7
LB - Libano 7
PA - Panama 7
TT - Trinidad e Tobago 7
AL - Albania 6
JO - Giordania 6
SV - El Salvador 6
TH - Thailandia 6
BH - Bahrain 5
BO - Bolivia 5
EE - Estonia 5
GR - Grecia 5
GT - Guatemala 5
NO - Norvegia 5
PE - Perù 5
CY - Cipro 4
DO - Repubblica Dominicana 4
ME - Montenegro 4
PR - Porto Rico 4
RS - Serbia 4
SN - Senegal 4
XK - ???statistics.table.value.countryCode.XK??? 4
AO - Angola 3
BY - Bielorussia 3
DK - Danimarca 3
ET - Etiopia 3
EU - Europa 3
GD - Grenada 3
GE - Georgia 3
HU - Ungheria 3
IL - Israele 3
KG - Kirghizistan 3
LV - Lettonia 3
MD - Moldavia 3
MM - Myanmar 3
Totale 24.288
Salva come PNG Salva come JPEG
Città #
Ashburn 1.546
Singapore 1.308
San Jose 1.108
Fairfield 826
Chandler 578
Hong Kong 479
Houston 443
Woodbridge 424
Moscow 343
Palermo 338
Wilmington 330
Seattle 321
Zgierz 305
Council Bluffs 296
Ann Arbor 278
Cambridge 258
Los Angeles 253
New York 225
Dallas 223
Beijing 196
Helsinki 194
Tokyo 190
Rome 173
Ho Chi Minh City 168
Hefei 156
The Dalles 154
Chicago 153
Lauterbourg 147
Santa Clara 140
Medford 134
Dublin 126
Boardman 117
Frankfurt am Main 111
Hanoi 109
Milan 104
Munich 102
Des Moines 94
Altamura 89
Princeton 89
Buffalo 87
San Diego 76
Jacksonville 75
Lawrence 72
Ludwigshafen am Rhein 72
São Paulo 62
London 61
Denver 55
Orem 55
Nanjing 51
Phoenix 50
Seoul 50
Toronto 50
Lappeenranta 49
Warsaw 47
Atlanta 44
Nuremberg 44
Montreal 43
Kitzingen 37
Brussels 35
Bremen 34
Brooklyn 34
Dearborn 33
Johannesburg 33
Jinan 31
Naples 31
San Francisco 31
Redondo Beach 30
Amsterdam 28
Changsha 28
Stockholm 28
Chennai 27
Haiphong 27
Tulsa 27
Guangzhou 24
Rio de Janeiro 23
Poplar 22
Baghdad 21
Boston 21
Philadelphia 21
Turin 21
Mexico City 20
Abidjan 19
Tianjin 19
Brasília 18
Manchester 18
Schiffdorf 18
Tashkent 18
Vienna 18
Bari 17
Columbus 17
Erbil 17
Shanghai 17
Shenyang 17
Turku 17
Washington 17
Kingston 16
Memphis 16
Pune 16
Salt Lake City 16
Tampa 16
Totale 14.665
Salva come PNG Salva come JPEG
Nome #
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM) 414
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 371
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 369
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 348
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 329
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 327
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer 320
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features 314
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 298
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 294
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients 283
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 283
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 282
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. 280
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 280
Liquid Biopsy in Breast Cancer 260
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 248
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 247
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 243
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 243
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 240
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report 238
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 237
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 231
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 231
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma 228
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 225
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. 222
Serum follistatin in patients with prostate cancer metastatic to the bone 219
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 219
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 217
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer 217
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 215
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER 213
Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread 212
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 211
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 210
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 210
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections 210
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives 202
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? 198
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. 196
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 195
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 194
Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer 194
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 189
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 189
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 188
Studio del pattern di distribuzione dell'Activina A nel siero di pazienti con metastasi ossee da carcinoma prostatico in trattamento con acido zoledronico 186
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 186
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin 184
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 183
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. 182
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 181
Liquid Biopsy in Gynecological Cancers 179
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 176
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? 175
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 173
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 171
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 168
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” 167
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors 167
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? 165
Liquid Biopsy in Gastrointestinal Stromal Tumor 164
Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women 162
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 161
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 160
Cancer of the Thyroid 159
Applications of Platelet Concentrates (PCs) in Regenerative Onco-Urology: A Systematic Review of Literature 158
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study 157
Clinical significance of Activin A serum levels in patients with primary osteoporosis: a preliminary report 157
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 156
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study. 156
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 155
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 154
Recent advances in desmoid tumor therapy 153
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome 153
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? 151
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients 150
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors 150
Current clinically validated applications of liquid biopsy 146
Molecular tumor board 145
Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography 145
I tumori stromali gastrointestinali: dalla biologia alla clinica 144
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3) 144
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? 144
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer 143
Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon 141
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 140
Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices 138
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 138
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials 138
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 138
Scientific Communication and oncology – "The bridge between knowledge and patients" 134
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors 130
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors 128
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 127
Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives 122
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 122
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 121
Totale 20.010
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.341
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.341
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022932 0 0 0 28 53 70 55 69 113 162 166 216
2022/20231.686 170 306 37 217 160 245 91 143 169 33 75 40
2023/20241.184 43 127 104 112 76 181 145 122 24 65 21 164
2024/20253.414 117 153 140 267 151 232 417 283 243 410 417 584
2025/202611.075 854 332 770 981 1.196 1.586 1.512 1.015 860 814 601 554
2026/20272.496 545 440 1.316 195 0 0 0 0 0 0 0 0
Totale 25.252